Vyne Therapeutics Inc. (VYNE) intrinsic value & 10-year financials
Vyne Therapeutics Inc. (VYNE) has a Graham intrinsic value of $1.48 per share. Over the last 10 fiscal years revenue shrank 1.8% a year to $570.0K, with an average return on invested capital of -278.7%.
- Graham intrinsic value
- $1.48
- Revenue (FY2025)
- $570.0K
- Revenue growth (10-yr CAGR)
- -1.8%
- ROIC (10-yr avg)
- -278.7%
- Free cash flow (FY2025)
- -$33.1M
VYNE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $570.0K | -$26.5M | -$0.62 | -$33.1M | -5219.1% | -165.7% |
| FY2024 | $501.0K | -$39.8M | -$0.93 | -$34.1M | -8710.0% | -96.6% |
| FY2023 | $424.0K | -$28.5M | -$0.69 | -$25.3M | -6900.5% | -100.0% |
| FY2022 | $477.0K | -$23.2M | -$1.82 | — | -7189.7% | -1026.8% |
| FY2021 | $14.8M | -$73.3M | $0.35 | -$56.4M | -461.1% | -664.8% |
| FY2020 | $21.0M | -$255.6M | $1.97 | -$137.2M | -1203.0% | -593.2% |
| FY2019 | $443.0K | -$73.7M | — | -$65.1M | -17210.4% | -107.2% |
| FY2018 | $3.6M | -$51.4M | — | -$52.9M | -1517.0% | -148.7% |
| FY2017 | $4.6M | -$29.1M | — | -$28.3M | -645.9% | 68.4% |
| FY2016 | $674.0K | -$14.1M | — | -$2.3M | -2126.4% | 47.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
VYNE Therapeutics Inc. is facing top-line stagnation, with revenue contracting over the decade.
VYNE Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -36.1% ROIC.
VYNE Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, VYNE Therapeutics Inc. is modeled at -1.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.48 per share.